Australian immuno-oncology company Imugene (ASX:IMU) has relocated to accelerate development of its lead cancer therapy after reporting encouraging clinical results,…
Read More

Australian immuno-oncology company Imugene (ASX:IMU) has relocated to accelerate development of its lead cancer therapy after reporting encouraging clinical results,…
Read More